Phosphorylation of different tau sites during progression of Alzheimer’s disease

Alzheimer’s disease is characterized by accumulation of amyloid plaques and tau aggregates in several cortical brain regions. Tau phosphorylation causes formation of neurofibrillary tangles and neuropil threads. Phosphorylation at tau Ser202/Thr205 is well characterized since labeling of this site is used to assign Braak stage based on occurrence of neurofibrillary tangles. Only little is known about the spatial and temporal phosphorylation profile of other phosphorylated tau (ptau) sites. Here, we investigate total tau and ptau at residues Tyr18, Ser199, Ser202/Thr205, Thr231, Ser262, Ser396, Ser422 as well as amyloid-β plaques in human brain tissue of AD patients and controls. Allo- and isocortical brain regions were evaluated applying rater-independent automated quantification based on digital image analysis. We found that the level of ptau at several residues, like Ser199, Ser202/Thr205, and Ser422 was similar in healthy controls and Braak stages I to IV but was increased in Braak stage V/VI throughout the entire isocortex and transentorhinal cortex. Quantification of ThioS-stained plaques showed a similar pattern. Only tau phosphorylation at Tyr18 and Thr231 was already significantly increased in the transentorhinal region at Braak stage III/IV and hence showed a progressive increase with increasing Braak stages. Additionally, the increase in phosphorylation relative to controls was highest at Tyr18, Thr231 and Ser199. By contrast, Ser396 tau and Ser262 tau showed only a weak phosphorylation in all analyzed brain regions and only minor progression. Our results suggest that the ptau burden in the isocortex is comparable between all analyzed ptau sites when using a quantitative approach while levels of ptau at Tyr18 or Thr231 in the transentorhinal region are different between all Braak stages. Hence these sites could be crucial in the pathogenesis of AD already at early stages and therefore represent putative novel therapeutic targets.

[1]  Alan J. Thomas,et al.  Quantitative neuropathology: an update on automated methodologies and implications for large scale cohorts , 2017, Journal of Neural Transmission.

[2]  Brian J Cummings,et al.  Early phosphorylation of tau in Alzheimer's disease occurs at Ser-202 and is preferentially located within neurites. , 1994, Neuroreport.

[3]  W. Noble,et al.  Tyrosine phosphorylation of tau regulates its interactions with Fyn SH2 domains, but not SH3 domains, altering the cellular localization of tau , 2011, The FEBS journal.

[4]  C. Geula,et al.  Comparative distribution of tau phosphorylated at Ser262 in pre-tangles and tangles , 2003, Neurobiology of Aging.

[5]  P. Hof,et al.  Tau Protein Hyperphosphorylation and Aggregation in Alzheimer’s Disease and Other Tauopathies, and Possible Neuroprotective Strategies , 2016, Biomolecules.

[6]  P. Davies,et al.  Hyperphosphorylation and aggregation of tau in mice expressing normal human tau isoforms , 2003, Journal of neurochemistry.

[7]  D. Moechars,et al.  Tau Positron Emission Tomography (PET) Imaging: Past, Present, and Future. , 2015, Journal of medicinal chemistry.

[8]  G. V. Van Hoesen,et al.  Phosphorylation of Tau by Fyn: Implications for Alzheimer's Disease , 2004, The Journal of Neuroscience.

[9]  D. Hanger,et al.  Membrane‐bound β‐amyloid oligomers are recruited into lipid rafts by a fyn‐dependent mechanism , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[10]  Jian-Zhi Wang,et al.  The effect of cdk-5 overexpression on tau phosphorylation and spatial memory of rat , 2010, Science in China Series C: Life Sciences.

[11]  J. Trojanowski,et al.  The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[12]  B. Winblad,et al.  Assessments of the accumulation severities of amyloid β-protein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brains , 2006, Neurobiology of Disease.

[13]  S. Tenreiro,et al.  Protein phosphorylation in neurodegeneration: friend or foe? , 2014, Front. Mol. Neurosci..

[14]  M. Billingsley,et al.  Regulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. , 1997, The Biochemical journal.

[15]  M. Ward,et al.  Tyrosine Phosphorylation of Tau by the Src Family Kinases Lck and Fyn , 2011, Molecular Neurodegeneration.

[16]  F. LaFerla,et al.  Nicotinamide Restores Cognition in Alzheimer's Disease Transgenic Mice via a Mechanism Involving Sirtuin Inhibition and Selective Reduction of Thr231-Phosphotau , 2008, The Journal of Neuroscience.

[17]  J. Cho,et al.  Primed phosphorylation of tau at Thr231 by glycogen synthase kinase 3β (GSK3β) plays a critical role in regulating tau's ability to bind and stabilize microtubules , 2003, Journal of neurochemistry.

[18]  H. Braak,et al.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry , 2006, Acta Neuropathologica.

[19]  L. Mucke,et al.  Amyloid-β/Fyn–Induced Synaptic, Network, and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer's Disease , 2011, The Journal of Neuroscience.

[20]  A. Atlante,et al.  Interaction between NH2-tau fragment and Aβ in Alzheimer's disease mitochondria contributes to the synaptic deterioration , 2012, Neurobiology of Aging.

[21]  Ger J. A. Ramakers,et al.  Improved Long-Term Potentiation and Memory in Young Tau-P301L Transgenic Mice before Onset of Hyperphosphorylation and Tauopathy , 2006, The Journal of Neuroscience.

[22]  M. Ciotti,et al.  Endogenous Aβ causes cell death via early tau hyperphosphorylation , 2011, Neurobiology of Aging.

[23]  L. Mucke,et al.  Amyloid-beta / Fyn – Induced Synaptic , Network , and Cognitive Impairments Depend on Tau Levels in Multiple Mouse Models of Alzheimer ’ s Disease , 2015 .

[24]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[25]  R. Cowburn,et al.  Tau‐Tubulin Kinase 1 Expression, Phosphorylation and Co‐Localization with Phospho‐Ser422 Tau in the Alzheimer's Disease Brain , 2013, Brain pathology.

[26]  John Q. Trojanowski,et al.  Abnormal tau phosphorylation at Ser396 in alzheimer's disease recapitulates development and contributes to reduced microtubule binding , 1993, Neuron.

[27]  K. Ye,et al.  SUMOylation at K340 inhibits tau degradation through deregulating its phosphorylation and ubiquitination , 2014, Proceedings of the National Academy of Sciences.

[28]  Xiongwei Zhu,et al.  Phosphorylation of Tau Protein as the Link between Oxidative Stress, Mitochondrial Dysfunction, and Connectivity Failure: Implications for Alzheimer's Disease , 2013, Oxidative medicine and cellular longevity.

[29]  Jürgen Götz,et al.  Dendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models , 2010, Cell.

[30]  C. Rowe,et al.  Amyloid imaging with PET in early Alzheimer disease diagnosis. , 2013, The Medical clinics of North America.

[31]  Agneta Nordberg,et al.  Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia , 2010, The Journal of Nuclear Medicine.

[32]  Andrew King,et al.  Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium , 2008, Brain pathology.

[33]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[34]  H. Paudel,et al.  Glycogen synthase kinase 3beta phosphorylates Alzheimer's disease-specific Ser396 of microtubule-associated protein tau by a sequential mechanism. , 2006, Biochemistry.

[35]  H. Paudel,et al.  Cyclin-dependent protein kinase 5 primes microtubule-associated protein tau site-specifically for glycogen synthase kinase 3beta. , 2006, Biochemistry.

[36]  Lin Xie,et al.  Radiosynthesis, Photoisomerization, Biodistribution, and Metabolite Analysis of 11C-PBB3 as a Clinically Useful PET Probe for Imaging of Tau Pathology , 2014, The Journal of Nuclear Medicine.

[37]  M. Strong,et al.  Thr175-phosphorylated tau induces pathologic fibril formation via GSK3β-mediated phosphorylation of Thr231 in vitro , 2015, Neurobiology of Aging.

[38]  C. Guerra-Araiza,et al.  Tau Phosphorylation in Female Neurodegeneration: Role of Estrogens, Progesterone, and Prolactin , 2018, Front. Endocrinol..

[39]  E. Mandelkow,et al.  Phosphorylation-dependent epitopes of neurofilament antibodies on tau protein and relationship with Alzheimer tau. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Petrucelli,et al.  Acetylation: a new key to unlock tau’s role in neurodegeneration , 2014, Alzheimer's Research & Therapy.

[41]  I. Everall,et al.  Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in Response to Amyloid-β Peptide Exposure: Involvement of Src Family Protein Kinases , 2002, The Journal of Neuroscience.

[42]  H. Jungwirth,et al.  Elevated Levels of Soluble Total and Hyperphosphorylated Tau Result in Early Behavioral Deficits and Distinct Changes in Brain Pathology in a New Tau Transgenic Mouse Model , 2012, Neurodegenerative Diseases.

[43]  Hyoung-Gon Lee,et al.  Cdk5 is a major regulator of p38 cascade: relevance to neurotoxicity in Alzheimer’s disease , 2010, Journal of neurochemistry.

[44]  B. Platt,et al.  Soluble pre-fibrillar tau and β-amyloid species emerge in early human Alzheimer’s disease and track disease progression and cognitive decline , 2016, Acta Neuropathologica.

[45]  F. García-Sierra,et al.  Regional conformational change involving phosphorylation of tau protein at the Thr231, precedes the structural change detected by Alz-50 antibody in Alzheimer's disease. , 2005, Journal of Alzheimer's disease : JAD.

[46]  J. Ávila,et al.  Post-translational modifications of tau protein. , 2006, Bratislavske lekarske listy.

[47]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.